Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
DR Wang, XL Wu, YL Sun - Signal transduction and targeted therapy, 2022 - nature.com
Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …
malignant cells but also an altered immune response. The inhibition and reprogramming of …
The foundations of immune checkpoint blockade and the ipilimumab approval decennial
AJ Korman, SC Garrett-Thomson… - Nature Reviews Drug …, 2022 - nature.com
Cancer immunity, and the potential for cancer immunotherapy, have been topics of scientific
discussion and experimentation for over a hundred years. Several successful cancer …
discussion and experimentation for over a hundred years. Several successful cancer …
Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy
The two T cell inhibitory receptors PD-1 and TIM-3 are co-expressed during exhausted T cell
differentiation, and recent evidence suggests that their crosstalk regulates T cell exhaustion …
differentiation, and recent evidence suggests that their crosstalk regulates T cell exhaustion …
Bioengineered nanogels for cancer immunotherapy
Recent years have witnessed increasingly rapid advances in nanocarrier-based
biomedicine aimed at improving treatment paradigms for cancer. Nanogels serve as …
biomedicine aimed at improving treatment paradigms for cancer. Nanogels serve as …
Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study
PURPOSE Pembrolizumab monotherapy has demonstrated durable antitumor activity in
advanced programmed death ligand 1 (PD-L1)–expressing non‒small-cell lung cancer …
advanced programmed death ligand 1 (PD-L1)–expressing non‒small-cell lung cancer …
Epigenetically controlled tumor antigens derived from splice junctions between exons and transposable elements
M Burbage, A Rocañín-Arjó, B Baudon, YA Arribas… - Science …, 2023 - science.org
Oncogenesis often implicates epigenetic alterations, including derepression of transposable
elements (TEs) and defects in alternative splicing. Here, we explore the possibility that …
elements (TEs) and defects in alternative splicing. Here, we explore the possibility that …
Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy
Advanced colorectal cancer is one of the deadliest cancers, with a 5-year survival rate of
only 12% for patients with the metastatic disease. Checkpoint inhibitors, such as the …
only 12% for patients with the metastatic disease. Checkpoint inhibitors, such as the …
Immune checkpoint inhibitors: basics and challenges
Cancer is one of the most deadly diseases in the modern world. The last decade has
witnessed dramatic advances in cancer treatment through immunotherapy. One extremely …
witnessed dramatic advances in cancer treatment through immunotherapy. One extremely …
Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments
Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target
tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune …
tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune …
ILC2-driven innate immune checkpoint mechanism antagonizes NK cell antimetastatic function in the lung
MJ Schuijs, S Png, AC Richard, A Tsyben… - Nature …, 2020 - nature.com
Metastasis constitutes the primary cause of cancer-related deaths, with the lung being a
commonly affected organ. We found that activation of lung-resident group 2 innate lymphoid …
commonly affected organ. We found that activation of lung-resident group 2 innate lymphoid …